Pfizer Inc. $PFE Stock Holdings Increased by Thornburg Investment Management Inc.

Thornburg Investment Management Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 52.0% during the 4th quarter, Holdings Channel reports. The fund owned 2,202,459 shares of the biopharmaceutical company’s stock after purchasing an additional 753,189 shares during the period. Thornburg Investment Management Inc.’s holdings in Pfizer were worth $54,841,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Horizon Financial Services LLC increased its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer during the 4th quarter valued at $28,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the 2nd quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $26.19 on Monday. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $149.26 billion, a price-to-earnings ratio of 19.99 and a beta of 0.34. The stock’s fifty day simple moving average is $26.43 and its 200-day simple moving average is $26.33.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the company posted $0.92 earnings per share. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. HSBC lifted their price target on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Wolfe Research reiterated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.82.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.